Honasa Consumer, the owner of beauty and personal care brand Mamaearth, saw its net profit nearly double in Q2 FY27 to Rs 73.2 crore on a 36% revenue increase, driven by strong demand across multiple sales channels and focus product categories.

  • Q2 FY27 net profit up 87% to Rs 73.2 crore
  • Revenue surged 36% to Rs 731.2 crore
  • Fluence Pharma acquisition plan called off

What happened

Honasa Consumer reported a consolidated net profit of Rs 73.2 crore for the second quarter of fiscal year 2026-27, marking an 87% increase compared to Rs 39.2 crore in the same quarter last year. Revenue from operations climbed 36% to Rs 731.2 crore from Rs 538.1 crore in Q2 FY26, reflecting broad-based growth across its portfolio.

The company also announced it had called off its previously approved acquisition plan for a 58% stake in Fluence Pharma due to the non-fulfillment of closing conditions. Meanwhile, Honasa established Honasa Health Private Ltd, a new wholly owned subsidiary set to operate its consumer nutraceutical business.

Why it matters

Honasa’s earnings and sales growth underscore the strength of its focus categories like face cleansers, shampoos, and skincare products, which grew over 40% year-on-year and now contribute more than 80% of the company's business. These segments demonstrated improved contribution margins and strong traction across e-commerce, general trade, and modern trade channels.

The company’s ability to maintain high revenue growth amidst a competitive beauty and personal care market in India signals its expanding footprint, with products now available at over 320,000 retail outlets nationwide. Along with Mamaearth, its other brands like Aqualogica, Dr. Sheth’s, and BBlunt experienced even faster growth, advancing Honasa’s ‘House of Brands’ strategy.

What to watch next

Investors will closely monitor Honasa's strategy execution around its focus categories to capture further market share in India’s estimated Rs 50,000 crore opportunity, where the company currently holds about 5%. Continued premiumization and market expansion remain key growth levers over the next three to five years.

Additionally, the performance and development of Honasa Health Private Ltd’s nutraceutical business will be important to watch, as the company invests in new segments beyond core beauty and personal care. Any future acquisitions or strategic shifts, especially considering the Fluence Pharma deal was halted, could also significantly impact Honasa’s growth trajectory.

Source assisted: This briefing began from a discovered source item from MediaNama. Open the original source.
How SignalDesk reports: feeds and outside sources are used for discovery. Public briefings are edited to add context, buyer relevance and attribution before they are published. Read the standards

Related briefings